A guide to cancer immunotherapy: from T cell basic science to clinical practice

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807

Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments

Geethakumari, P. R., Ramasamy, D. P., Dholaria, B., Berdeja, J. G., & Kansagra, A. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00635-3 · Cited by 67

Trial watch: intratumoral immunotherapy

Humeau, J., Naour, J. L., Galluzzi, L., Kroemer, G., & Pol, J. G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1984677 · Cited by 62

Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy

Yoo, Y. J., Lee, C. H., Park, S. H., & Lim, Y. T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.047 · Cited by 62

Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhimurium VNP20009 in anti-PD1 therapy against melanoma

Wu, L., Li, L., Li, S., Liu, L., Xin, W., Li, C., Yin, X., Xu, X., Bao, F., & Hua, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.006 · Cited by 64

Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer

Boon, S. S., Luk, H. Y., Xiao, C.-Y., Chen, Z., & Chan, P. K. S. (2022) · Cancers · doi:10.3390/cancers14122913 · Cited by 69

Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1

Mortezaee, K., & Majidpoor, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114824 · Cited by 63

Targets of tumor microenvironment for potential drug development

Zhang, L., Wang, Z., Liu, K., Liu, Y., Wang, S., Jiang, W., Lu, F., & Dang, Y. (2024) · MedComm – Oncology · doi:10.1002/mog2.68 · Cited by 68

The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response

Moatti, A., & Cohen, J. L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.725473 · Cited by 65

Exhausted CD8+ T cells face a developmental fork in the road

Zander, R., & Cui, W. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.02.006 · Cited by 65

Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and T‐Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy

Dong, J., Miao, J., Miao, Y., Qu, Z., Zhang, S., Zhu, P., Wiede, F., Jassim, B. A., Bai, Y., Nguyen, Q. D., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202303818 · Cited by 60

Application of oncolytic virus in tumor therapy

Huang, Z., Guo, H., Lin, L., Li, S., Yang, Y., Han, Y., Huang, W., & Yang, J. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28729 · Cited by 61

Light-responsive nanomedicine for cancer immunotherapy

Kang, W., Liu, Y., & Wang, W. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.016 · Cited by 64

New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies

Pathania, A. S., Prathipati, P., & Challagundla, K. B. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188624 · Cited by 62

Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors

Lian, G., Mak, T. S., Yu, X., & Lan, H. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010164 · Cited by 63

Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials

Yadav, D., Kwak, M., Chauhan, P., Puranik, N., Lee, P. C.-W., & Jin, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.016 · Cited by 58

Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy

Kim, J., & Thomas, S. N. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000500 · Cited by 60

Extracellular vesicles as next generation immunotherapeutics

Greening, D. W., Xu, R., Ale, A., Hagemeyer, C. E., & Chen, W. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.002 · Cited by 61

Cancer Cell Membrane Nanodiscs for Antitumor Vaccination

Guo, Z., Noh, I., Zhu, A. T., Yu, Y., Gao, W., Fang, R. H., & Zhang, L. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c01775 · Cited by 60

Aged intestinal stem cells propagate cell-intrinsic sources of inflammaging in mice

Funk, M. C., Gleixner, J., Heigwer, F., Vonficht, D., Valentini, E., Aydin, Z., Tonin, E., Prete, S., Mahara, S., Throm, Y., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.11.013 · Cited by 62

Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation

Zhang, Y., Yeganeh, P. N., Zhang, H., Wang, S. Y., Li, Z., Gu, B., Lee, D.-J., Zhang, Z., Ploumakis, A., Shi, M., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01932-8 · Cited by 64

Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy

Izzo, D., Ascione, L., Guidi, L., Marsicano, R. M., Koukoutzeli, C., Trapani, D., & Curigliano, G. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241309461 · Cited by 61

Host-Directed Therapies for Cutaneous Leishmaniasis

Novais, F. O., Amorim, C. F., & Scott, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660183 · Cited by 57

Immunity beyond cancer cells: perspective from tumor tissue

Gao, S., Hsu, T.-W., & Li, M. O. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.06.007 · Cited by 58

High-Throughput 3D In Vitro Tumor Vasculature Model for Real-Time Monitoring of Immune Cell Infiltration and Cytotoxicity

Song, J., Choi, H., Koh, S. K., Park, D., Yu, J., Kang, H., Kim, Y., Cho, D., & Jeon, N. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733317 · Cited by 60

Silk Embolic Material for Catheter‐Directed Endovascular Drug Delivery

Hu, J., Albadawi, H., Zhang, Z., Salomao, M. A., Gunduz, S. G., Rehman, S., d’Amone, L., Mayer, J. L., Omenetto, F. G., & Öklü, R. (2021) · Advanced Materials · doi:10.1002/adma.202106865 · Cited by 59

Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements

Yun, C., Hong, J., & Yoon, A. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953410 · Cited by 62

Impact of sarcopenia on the prognosis and treatment of lung cancer: an umbrella review

Lin, T.-Y., Chen, Y., Wu, W., Han, D., Tsai, I., Chang, K. C., & Özçakar, L. (2022) · Discover Oncology · doi:10.1007/s12672-022-00576-0 · Cited by 65

Emergence of magnetic nanoparticles in photothermal and ferroptotic therapies

de Walle, A. V., Figuerola, A., Espinosa, A., Abou‐Hassan, A., Estrader, M., & Wilhelm, C. (2023) · Materials Horizons · doi:10.1039/d3mh00831b · Cited by 60

Visualizing vasculature and its response to therapy in the tumor microenvironment

Lin, Q., Choyke, P. L., & Sato, N. (2023) · Theranostics · doi:10.7150/thno.84947 · Cited by 68

Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides

Ferreira, H. J., Stevenson, B. J., Pak, H., Yu, F., Oliveira, J., Huber, F., Taillandier-Coindard, M., Michaux, J., Altimiras, E. R., Kraemer, A. I., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46408-3 · Cited by 61

Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.

Godakhindi, V., Tarannum, M., Dam, S. K., & Vivero-Escoto, J. L. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400323 · Cited by 65

Cancer vaccines: platforms and current progress

Lei, W., Zhou, K., Lei, Y., Qiu, L., & Zhu, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00241-8 · Cited by 66

RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets

Pan, Y., Kadash-Edmondson, K. E., Wang, R., Phillips, J., Liu, S., Ribas, A., Aplenc, R., Witte, O. N., & Xing, Y. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.006 · Cited by 59

Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy

Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 62

Engineering mannosylated pickering emulsions for the targeted delivery of multicomponent vaccines

Du, Y., Song, T., Wu, J., Gao, X., Ma, G., Liu, Y., & Xia, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121313 · Cited by 58

The multiple roles of salt-inducible kinases in regulating physiology

Jagannath, A., Taylor, L., Ru, Y., Wakaf, Z., Akpobaro, K., Vasudevan, S. R., & Foster, F. (2023) · Physiological Reviews · doi:10.1152/physrev.00023.2022 · Cited by 64

Artificial intelligence in cancer immunotherapy: Applications in neoantigen recognition, antibody design and immunotherapy response prediction

Li, T., Li, Y., Zhu, X., He, Y., Wu, Y., Ying, T., & Xie, Z. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.007 · Cited by 60

Chimeric antigen receptor engineered natural killer cells for cancer therapy

Zhang, Y., Zhou, W., Yang, J., Yang, J., & Wang, W. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00431-0 · Cited by 58

VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy

Shekari, N., Shanehbandi, D., Kazemi, T., Zarredar, H., Baradaran, B., & Jalali, S. A. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03116-0 · Cited by 58

Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions

Mei, S., Alchahin, A. M., Τσέα, Ι., Kfoury, Y. S., Hirz, T., Jeffries, N. E., Zhao, T., Xu, Y., Zhang, H., Sarkar, H., et al. (2024) · Genome Medicine · doi:10.1186/s13073-023-01272-6 · Cited by 59

Illness trajectories of incurable solid cancers

Geijteman, E. C. T., Kuip, E. J. M., Oskam, J., Lees, D. C., & Bruera, E. D. (2024) · BMJ · doi:10.1136/bmj-2023-076625 · Cited by 68

Cardiotoxic mechanisms of cancer immunotherapy – A systematic review

Lobenwein, D., Kocher, F., Dobner, S., Gollmann‐Tepeköylü, C., & Holfeld, J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.033 · Cited by 59

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve

Fabian, K. P., Padget, M. R., Fujii, R., Schlom, J., & Hodge, J. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001691 · Cited by 59

Mechanobiology of T Cell Activation: To Catch a Bond

Liu, B., Kolawole, E. M., & Evavold, B. D. (2021) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-120219-055100 · Cited by 59

Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer

Kemp, S. B., di Magliano, M. P., & Crawford, H. C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.07.006 · Cited by 64

Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies

Zhao, N., & Rosen, J. M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.010 · Cited by 58

Locally sourced: site-specific immune barriers to metastasis

Correia, A. L. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00836-2 · Cited by 59

Engineering cells for precision drug delivery: New advances, clinical translation, and emerging strategies

Chao, C.-J., Zhang, E., & Zhao, Z. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114840 · Cited by 59

Modular Hydrogel Vaccine for Programmable and Coordinate Elicitation of Cancer Immunotherapy

Ji, P., Sun, W., Zhang, S., Xing, Y., Wang, C., Wei, M., Li, Q., Ji, G., & Yang, G. (2023) · Advanced Science · doi:10.1002/advs.202301789 · Cited by 57

Tumor cell–derived spermidine is an oncometabolite that suppresses TCR clustering for intratumoral CD8 + T cell activation

Hibino, S., Eto, S., Hangai, S., Endo, K., Ashitani, S., Sugaya, M., Osawa, T., Soga, T., Taniguchi, T., & Yanai, H. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305245120 · Cited by 58

Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial

Rodrigues, M. J., Vanoni, G., Loap, P., Dubot, C., Timperi, E., Minsat, M., Bazire, L., Durdux, C., Fourchotte, V., Laas, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39383-8 · Cited by 58

Role of stress granules in tumorigenesis and cancer therapy

Li, T., Zeng, Z., Fan, C., & Xiong, W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189006 · Cited by 56

Copper(II)-Based Nano-Regulator Correlates Cuproptosis Burst and Sequential Immunogenic Cell Death for Synergistic Cancer Immunotherapy

Luo, Y., Luo, X., Ru, Y., Zhou, X., Liu, D., Huang, Q., Linghu, M., Wu, Y., Lv, Z., Chen, M., et al. (2024) · Biomaterials Research · doi:10.34133/bmr.0039 · Cited by 61

Extracellular vesicles-based vaccines: Emerging immunotherapies against cancer

Meng, Y., Yao, Z., Ke, X., Hu, M., Ren, H., Gao, S., & Zhang, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.010 · Cited by 56

Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?

Zuo, S., Song, J., Zhang, J., He, Z., Sun, B., & Sun, J. (2021) · Theranostics · doi:10.7150/thno.59953 · Cited by 56

Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment

Shariq, O. A., & McKenzie, T. J. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211033103 · Cited by 63

Glioblastoma, from disease understanding towards optimal cell-based in vitro models

Boccellato, C., & Rehm, M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00684-7 · Cited by 56

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer

Dumitru, A. V., Dobrică, E.-C., Croitoru, A. E., Creţoiu, S. M., & Gașpar, B. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012067 · Cited by 56

CAF-immune cell crosstalk and its impact in immunotherapy

Maia, A. R. R., Schöllhorn, A., Schuhmacher, J., & Gouttefangeas, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00977-x · Cited by 61

The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer

Arif, A., Alameri, A. A., Tariq, U. B., Ansari, S. A., Sakr, H. I., Qasim, M. T., Al-joborae, F. F. M., Ramírez‐Coronel, A. A., Jabbar, H. S., Gabr, G. A., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109581 · Cited by 66

Cloaking Mesoporous Polydopamine with Bacterial Membrane Vesicles to Amplify Local and Systemic Antitumor Immunity

Chen, W., Song, Y., Bai, S., He, C., Guo, Z., Zhu, Y., Zhang, Z., & Sun, X. (2023) · ACS Nano · doi:10.1021/acsnano.3c00363 · Cited by 57

Cancer organoids: A platform in basic and translational research

Ma, X., Wang, Q. L., Li, G., Li, H., Xu, S., & Pang, D. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.052 · Cited by 62

Microbiota and Colorectal Cancer: From Gut to Bedside

Silva, M. G., Brunner, V., & Tschurtschenthaler, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760280 · Cited by 61

Metal‐Cyclic Dinucleotide Nanomodulator‐Stimulated STING Signaling for Strengthened Radioimmunotherapy of Large Tumor

Wang, D., Nie, T., Huang, C., Chen, Z., Ma, X., Fang, W., Huang, Y., Luo, L., & Xiao, Z. (2022) · Small · doi:10.1002/smll.202203227 · Cited by 55

Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets

Alahdal, M., & Elkord, E. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1425 · Cited by 55

ROS regulation in gliomas: implications for treatment strategies

Yang, Y.-C., Zhu, Y., Sun, S.-J., Zhao, C.-J., Bai, Y., Wang, J., & Ma, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259797 · Cited by 56

Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications

Masarwy, R., Stotsky‐Oterin, L., Elisha, A., Hazan‐Halevy, I., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115359 · Cited by 59

Engineering Versatile Bacteria‐Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy

Luo, Z., Cheng, X., Feng, B., Fan, D., Liu, X., Xie, R., Luo, T., Wegner, S. V., Ma, D., Chen, F., et al. (2024) · Advanced Science · doi:10.1002/advs.202400049 · Cited by 55

Leveraging Single-Cell Approaches in Cancer Precision Medicine

Nath, A., & Bild, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.007 · Cited by 57

Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana‐Farber Cancer Institute, 2011 to 2019

Xu, Y., Wen, N., Sonis, S. T., & Villa, A. (2021) · Cancer · doi:10.1002/cncr.33436 · Cited by 61

Recent Progress in Dendritic Cell-Based Cancer Immunotherapy

Matsuo, K., Yoshie, O., Kitahata, K., Kamei, M., Hara, Y., & Nakayama, T. (2021) · Cancers · doi:10.3390/cancers13102495 · Cited by 54

Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy

Levin, N., Paria, B. C., Vale, N. R., Yossef, R., Lowery, F. J., Parkhurst, M. R., Yu, Z., Florentin, M., Cafri, G., Gartner, J. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0849 · Cited by 54

Recent advancements in lipid–mRNA nanoparticles as a treatment option for cancer immunotherapy

Karmacharya, P., Patil, B. R., & Kim, J. O. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00569-9 · Cited by 54

Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy

Dong, X., Pan, P., Ye, J., Zhang, Q., & Zhang, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121763 · Cited by 58

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

Wattenberg, M. M., Coho, H., Herrera, V. M., Graham, K. L., Stone, M. L., Xue, Y., Chang, R. B., Cassella, C. R., Liu, M., Choi-Bose, S., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adj5097 · Cited by 53

ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 63

Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis

Su, J., Yu-ning, L., Tan, S., Cheng, T., Luo, Y., & Zhang, L. (2025) · Scientific Reports · doi:10.1038/s41598-024-84890-3 · Cited by 60

Chiral polypeptide hydrogels regulating local immune microenvironment and anti-tumor immune response

Ding, J., Wang, T., Lin, Z., Li, Z., Yang, J., Li, F., Rong, Y., Chen, X., & He, C. (2025) · Nature Communications · doi:10.1038/s41467-025-56137-w · Cited by 60

Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study

Huang, Z., Karaboué, A., Zeng, L., Lecoeuvre, A., Zhang, L., Li, X., Qin, H., Danino, G., Yang, F., Malin, M.-S., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105607 · Cited by 54

The immune suppressive microenvironment affects efficacy of radio‐immunotherapy in brain metastasis

Niesel, K., Schulz, M., Anthes, J., Alekseeva, T., Macas, J., Salamero‐Boix, A., Möckl, A., Oberwahrenbrock, T., Lolies, M., Stein, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013412 · Cited by 56

Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab

Dall’Olio, F. G., Calabrò, D., Conci, N., Argalia, G., Marchese, P. V., Fabbri, F., Fragomeno, B., Ricci, D., Fanti, S., Ambrosini, V., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.020 · Cited by 53

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression

Fontana, F., Anselmi, M., & Limonta, P. (2022) · Cancers · doi:10.3390/cancers14071614 · Cited by 53

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy

Liu, X., Xu, Y., Xiong, W., Yin, B., Huang, Y., Chu, J., Xing, C., Chen, Q., Du, Y., Duan, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004035 · Cited by 53

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment

Singh, V., Sheikh, A., Abourehab, M. A. S., & Kesharwani, P. (2022) · Biosensors · doi:10.3390/bios12080617 · Cited by 53

Melanin-Based Immunoregulatory Nanohybrids Enhance Antitumor Immune Responses in Breast Cancer Mouse Model

Guo, K., Jiao, Z., Zhao, X., Hu, Y., Zhao, N., & Xu, F. (2023) · ACS Nano · doi:10.1021/acsnano.3c02287 · Cited by 53

Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy

Bie, N., Yong, T., Wei, Z., Liang, Q., Zhang, X., Li, S., Li, X., Li, J., Gan, L., & Yang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01658-3 · Cited by 53

Recent Advances in Pharmaceutical Design: Unleashing the Potential of Novel Therapeutics

Prajapati, R. N., Bhushan, B., Singh, K., Chopra, H., Kumar, S., Agrawal, M., Pathak, D., Chanchal, D. K., & Kant, L. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010275850240102105033 · Cited by 62

Rational Design of Lipid Nanoparticles for Enhanced mRNA Vaccine Delivery via Machine Learning

Bae, S., Choi, H., Lee, J., Kang, M., Ahn, S., Lee, Y., Choi, H., Jo, S., Lee, Y., Park, H., et al. (2024) · Small · doi:10.1002/smll.202405618 · Cited by 55

CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation

Chen, S., Wang, Y., Dang, J., Song, N., Chen, X., Wang, J., Huang, G. N., Brown, C. E., Yu, J., Weissman, I. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59326-9 · Cited by 60

Mechanisms of measles virus oncolytic immunotherapy

Pidelaserra-Martí, G., & Engeland, C. E. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.009 · Cited by 53

Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC

Yang, Y., Zhao, T., Chen, Q., Li, Y., Xiao, Z., Xiang, Y., Wang, B., Qiu, Y., Tu, S., Jiang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202202797 · Cited by 52

FDG PET/CT-based response assessment in malignancies

Parihar, A. S., Dehdashti, F., & Wahl, R. L. (2023) · RadioGraphics · doi:10.1148/rg.220122 · Cited by 53

Non-cytomembrane PD-L1: An atypical target for cancer

Ying, H., Zhang, X., Duan, Y., Lao, M., Xu, J., Yang, H., Liang, T., & Bai, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105741 · Cited by 54

Function and therapeutic development of exosomes for cancer therapy

Kim, S. B. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01387-1 · Cited by 52

Dual-functional alginate and collagen–based injectable hydrogel for the treatment of cancer and its metastasis

Hwang, J., An, E., Zhang, W., Kim, H., Eom, Y., & Jin, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01458-x · Cited by 52

Engineering nanosystems to overcome barriers to cancer diagnosis and treatment

Alhaj-Suliman, S. O., Wafa, E. I., & Salem, A. K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114482 · Cited by 53

Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity

Liu, L., Li, S., Qu, Y., Bai, H., Pan, X., Wang, J., Wang, Z., Duan, J., Zhong, J., Wan, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101206 · Cited by 54

Promoting the Recruitment, Engagement, and Reinvigoration of Effector T Cells via an Injectable Hydrogel with a Supramolecular Binding Capability for Cancer Immunotherapy

Zhu, Y., Jin, L., Chen, J., Su, M., Sun, T., & Yang, X. (2023) · Advanced Materials · doi:10.1002/adma.202309667 · Cited by 54

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Bol, K. F., Schreibelt, G., Bloemendal, M., van Willigen, W. W., Bree, S. H.-D., de Goede, A. L., de Boer, A. J., Bos, K., Boer, T. D., Nordkamp, M. A. M. O., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45358-0 · Cited by 59

Artificial urinary biomarker probes for diagnosis

Xu, C., & Pu, K. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00153-w · Cited by 58

Understanding of Antigen and Phenotypic Plasticity Molecules for the Purpose of Cancer Immunotherapy

Malviya, R., Singh, A. K., & Yadav, D. (2024) · Apple Academic Press eBooks · doi:10.1201/9781003533955-4

Role of T cells in cancer immunotherapy: Opportunities and challenges

Ahmed, H., Mahmud, A. R., Siddiquee, M. F. R., Shahriar, A., Biswas, P., Shimul, M. E. K., Ahmed, S. Z., Ema, T. I., Rahman, N., Khan, M. A., et al. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.12.002 · Cited by 148

Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer

Ali, S., Arshad, M., Summer, M., Zulfiqar, M., Noor, S., Nazakat, L., & Javed, M. A. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251324896 · Cited by 10

T Lymphocyte–Based Cancer Immunotherapeutics

Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 27

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211